AMD3100, which is an SDF-1α/CXCR4 inhibitor approved by the FDA, has been shown to mitigate radiation-induced skin damage and fibrosis [95] and is used to treat hematopoietic stem cell mobilization for stem cell transplantation in patients with certain types of cancer [96,97]. This evidence concerns the gene CXCR4 and cancer.